Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

DATRON AG (DAR.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
11.000.00 (0.00%)
At close: 05:36PM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.00
Open11.20
Bid11.00 x 50000
Ask11.40 x 135400
Day's Range11.00 - 11.20
52 Week Range10.40 - 13.20
Volume981
Avg. Volume504
Market Cap43.827M
Beta (5Y Monthly)0.93
PE Ratio (TTM)15.07
EPS (TTM)0.73
Earnings DateNov 04, 2021
Forward Dividend & Yield0.05 (0.40%)
Ex-Dividend DateJun 28, 2021
1y Target Est15.40
  • Business Wire

    GenSight Biologics: Annual General Meeting on May 25, 2022

    PARIS, May 04, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 25, 2022, at 9:00 am CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France (*).

  • Business Wire

    GenSight Biologics Granted Six-Month Extension in LUMEVOQ® European Regulatory Review

    PARIS, April 14, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA) has granted the Company a six-month extension for submitting its responses to the Day 120 questions in the regulator

Advertisement
Advertisement